TrialPloS one2015

A randomized, double blind, placebo-controlled, multicenter phase II trial of Allisartan Isoproxil in essential hypertensive population at low-medium risk.

Ying Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.